Yafour, N.
13  results:
Search for persons X
?
2

First experience of the use of a generic of plerixafor in p..:

Bekadja, M.A. ; Mansour, B. ; Ouldjeriouat, H....
Transfusion and Apheresis Science.  60 (2021)  3 - p. 103070 , 2021
 
?
3

Outcomes of modified-eam conditioned autologous non-cryopre..:

Bekadja, M. A. ; Talhi, S. ; Amani, K....
Bone Marrow Transplantation.  53 (2018)  12 - p. 1596-1598 , 2018
 
?
4

How to prevent relapse after allogeneic hematopoietic stem ..:

Yafour, N. ; Beckerich, F. ; Bulabois, C.E....
Current Research in Translational Medicine.  65 (2017)  2 - p. 65-69 , 2017
 
?
5

Cyclosporine-related brainstem atypical posterior reversibl..:

Yafour, N. ; Krim, A. ; Bouhass, R..
Hematology/Oncology and Stem Cell Therapy.  9 (2016)  1 - p. 36-38 , 2016
 
?
6

Plerixafor in the treatment of progenitor cell mobilization..:

Bekadja, M.A. ; Bouhass, R. ; Osmani, S....
Hematology/Oncology and Stem Cell Therapy.  8 (2015)  2 - p. 93-94 , 2015
 
?
7

La contribution de la collaboration pharmacien-clinicien da..:

Mazouz, I. ; Baghriche, I. ; Mekaouche, F.Z.N....
Le Pharmacien Hospitalier et Clinicien.  49 (2014)  2 - p. e37-e38 , 2014
 
?
9

Biosimilar G-CSF (filgrastim) is effective for peripheral b..:

Yafour, N. ; Brahimi, M. ; Osmani, S....
Transfusion Clinique et Biologique.  20 (2013)  5-6 - p. 502-504 , 2013
 
?
10

The use of granulocyte colony stimulating factoR (G-CSF) (f..:

Talhi, S. ; Osmani, S. ; Brahimi, M....
Transfusion and Apheresis Science.  49 (2013)  1 - p. 97-99 , 2013
 
1-13